

Amgen (AMGN)

Healthcare / Drug Manufacturers - General

StockRover

Stock Report | July 19, 2025

\$294.76 **-\$3.49 (-1.17%)** as of Friday's close

Cap (\$M USD)
\$158,494

P/E
26.9

EPS (1Y)
89.1%

Dividend
\$9.52

Last Filing
03/31/25

52-wk Range

\$253.30  \$346.85

Sales (\$M)
34,126

Fwd. P/E
13.7


Sales (1Y)
10.3%

Fwd. Yield
3.2%

Next Earnings
08/05/25

Dividend Adjusted Return Jul 18, 2024 - Jul 18, 2025

AMGN 294.76 (-9.4%) **Healthcare 243.33 (-10.6%)** **S&P 500 6296.79 (+14.1%)**



AMGN has underperformed the S&P 500 by -23.4% in the past year.

AMGN has performed nearly in line with its sector over the past year.






The Healthcare sector has underperformed the market by -24.6% in the past year.

ANALYST CONSENSUS

Buy

The consensus rating is unchanged from 1 month ago.




Strong Buy  12
Buy  2
Hold  15
Sell  1
Strong Sell  2

QUANTITATIVE SCORES

Fair Value \$308.06

Margin of Safety 5%

The Margin of Safety is the difference between a company's Fair Value and the current price. See more on page 8.

 **2 warnings**
Details on Page 8

Value Score

80

Value Score: Our value score looks at EV/EBITDA, P/E, P/S, P/TB (Price/Tangible Book) and EPS Predictability. P/S and P/TB are compared within a sector. Other metrics are compared across all stocks

Quality Score

84

Quality Score: Our quality score compares profitability and balance sheet metrics to find high quality companies using ROIC, Net Margin, Gross Margin, Interest Coverage, and Debt / Equity metrics.

Growth Score

90

Growth Score: Our growth score looks at the 5 year history and the forward estimates for EBITDA, Sales, and EPS growth, ranking the best companies across all stocks.

Sentiment Score

54

Sentiment Score: Our sentiment score finds stocks in favor by analyzing Short Interest, returns in key periods over the last year, Price vs. 52-wk High, Days Since 52-wk High and MACD signals.

BUSINESS SUMMARY




Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Employees 28,000

Homepage www.amgen.com


Headquarters Thousand Oaks, CA

VALUATION SUMMARY

	AMGN	Industry	S&P 500
Value Score	80	67	70
Price / Earnings	26.9	24.4	30.0
Price / Sales	4.7	4.0	3.3
Price / Free Cash Flow	14.6	20.2	40.3
Price / Book	25.5	5.4	5.5
Price / Tangible Book	-	-	500+
EV / EBITDA	13.5	18.6	25.2
EPS Predict. Pctl.	78	73	71
Piotroski F Score	6	7	6
5-Year P/E Range	14.9		56.6
5-Year P/B Range	11.7		148.6
5-Year P/S Range	4.2		6.5


GROWTH SUMMARY


	AMGN	Industry	S&P 500
Growth Score	90	72	76
Sales Growth			
Sales Growth Next Year	1.9%	7.9%	10.5%
Sales 1-Year Chg (%)	10.3%	10.7%	7.3%
Sales 3-Year Avg (%)	8.9%	-1.6%	7.9%
Sales 5-Year Avg (%)	7.0%	4.3%	11.1%
EPS Growth			
Next Yr. Growth Est.	3.1%	19.5%	14.3%
EPS 1-Year Chg (%)	89.1%	36.4%	10.1%
EPS 3-Year Avg (%)	-2.3%	0.6%	7.7%
EPS 5-Year Avg (%)	-2.2%	4.7%	14.9%


PEERS ANALYSIS SUMMARY

Ticker	Company	Cap (\$M USD)	P/E	Fwd. Yield	1M Return	1Y Return	Margin of Safety	Value Score	Growth Score	Quality Score
JNJ	Johnson & Johnson	\$393,874	17.5	3.2%	8.6%	8.8%	-3%	79	78	96
ABBV	AbbVie	\$334,309	80.7	3.5%	2.9%	14.5%	2%	65	81	74
NVS	Novartis	\$224,891	16.7	3.5%	-1.5%	10.5%	2%	87	70	97
AZN	AstraZeneca	\$212,420	27.7	2.3%	-2.8%	-10.1%	9%	73	94	92
MRK	Merck & Co	\$200,782	11.6	4.1%	0.8%	-33.5%	24%	87	87	97
AMGN	Amgen	\$158,494	26.9	3.2%	1.8%	-8.1%	5%	80	90	84
PFE	Pfizer	\$139,120	17.7	7.0%	2.5%	-12.1%	30%	83	58	82
GILD	Gilead Sciences	\$134,618	22.7	2.9%	0.2%	52.0%	23%	75	82	93
SNY	Sanofi	\$116,423	16.6	4.6%	1.5%	0.2%	24%	88	85	87
BMJ	Bristol-Myers Squibb	\$96,381	17.7	5.2%	2.4%	17.0%	19%	87	44	82
TAK	Takeda Pharmace...	\$46,504	63.7	4.6%	-3.2%	11.9%	29%	78	65	62
BIIB	Biogen	\$18,314	12.4	-	-1.2%	-44.5%	33%	95	55	89

PROFITABILITY SUMMARY

	AMGN	Industry	S&P 500
Quality Score	84	80	76
Gross Margin	63.0%	72.3%	31.6%
Operating Margin	21.8%	24.4%	15.1%
Net Margin	17.4%	16.2%	11.2%
Return on Assets	6.5%	9.6%	10.9%
Return on Equity	95.6%	31.9%	34.6%
ROIC	14.1%	17.9%	24.8%




RETURNS SUMMARY

	AMGN	Industry	S&P 500
Sentiment Score	54	46	56
5-Day Return	-0.2%	-1.6%	0.6%
1-Month Return	1.8%	0.2%	5.6%
YTD Return	15.0%	4.1%	7.7%
1-Year Return	-8.1%	-8.1%	15.0%
3-Year Return	33.0%	16.9%	71.5%
5-Year Return	33.3%	34.5%	109.8%
Beta 1-Year	0.48	0.39	1.00

Dividend Adjusted Return Jul 18, 2024 - Jul 18, 2025

AMGN 301.00 (-7.7%)




DIVIDEND

	AMGN	Industry
Forward Dividend Yield	3.2%	2.9%
Payout Ratio	82.6%	66.1%
TTM Yield	3.1%	-
Fwd. Div. Per Share	\$9.52	\$4.4
Div. 1Y Chg (%)	5.8%	10.5%
Div. 3Y Avg (%)	7.1%	5.5%
Div. 5Y Avg (%)	8.3%	6.0%
Cons. Growth Years	10+	-
Div. Coverage Ratio	1.2	1.4

DEBT & EQUITY

Current Ratio	1.2
Quick Ratio	0.9
Price	\$294.76
Net Cash Per Share	-\$90.51
Equity Per Share	\$11.54
Debt / Equity	9.2
Solvency Ratio	15%
Interest Coverage	3.2
Short % of Float	2.5%
Altman Z-Score	1.4

Debt / Equity 9.2



ANALYST REVISIONS

Current Quarter EPS		Next Quarter EPS	
# Up Last 30 days	5.00	# Up Last 30 days	6.00
# Down Last 30 days	12.00	# Down Last 30 days	11.00
Mean Estimate	5.23	Mean Estimate	5.38
% Change (30 Days)	-	% Change (30 Days)	-

MEAN ESTIMATE TREND

	Cur Qtr	Next Qtr	Cur Year	Next Year
Latest	\$5.23	\$5.38	\$20.85	\$21.49
30 Days Ago	\$5.23	\$5.38	\$20.84	\$21.48
90 Days Ago	\$5.34	\$5.52	\$20.64	\$21.56
% Change (90 Days)	-2.1%	-2.5%	1.0%	-0.3%

EARNINGS SURPRISES

Earnings surprise is the difference between a company's announced earnings and the average analyst estimated value. Surprises typically causes the stock price to jump and are often followed by more of the same surprise type.

Surprise Detail (Last 6 Quarters)

Surprise Summary (Last 12 Quarters)


Surprise Type	Amount	Percent
Positive Quarters (> 2%)	10	83.3%
Negative Quarters (< 2%)	0	-
In-Line Quarters (within 2%)	2	16.7%

Surprise Type	Announce Date	Period End Date	Actual EPS	Est. EPS	Surprise (%)
Positive	05/01/25	03/31/25	\$4.90	\$4.30	14.0%
Positive	02/04/25	12/31/24	\$5.31	\$5.08	4.5%
Positive	10/30/24	09/30/24	\$5.58	\$5.11	9.2%
In-Line	08/06/24	-	\$4.97	\$5.01	-0.8%
Positive	05/02/24	-	\$3.96	\$3.87	2.3%
Positive	02/06/24	-	\$4.71	\$4.61	2.2%

RISK


	AMGN	Industry	S&P 500
Best Monthly Return (5Y)	17.3%	7.7%	9.4%
Worst Monthly Return (5Y)	-15.6%	-8.0%	-9.6%
Beta 1-Year	0.48	0.39	1.00
Volatility 1-Year	0.26	0.18	0.19
Volatility 1Y Pctl.	24	-	-
Max Drawdown 1-Year	-22.7%	-27.6%	-18.7%
Max Drawdown 3-Year	-24.9%	-32.2%	-18.7%
Max Drawdown 5-Year	-24.9%	-33.8%	-24.6%

AMGN Volatility 1-Year 0.3



SEASONALITY

Seasonal Performance vs the S&P 500



5-YEAR RELATIVE PERFORMANCE VS S&P 500

Relative to the S&P 500 baseline, AMGN has underperformed the S&P 500 by -75.4% in the past 5 Years.

AMGN has outperformed its sector by 5.5% in the past 5 Years.

The Healthcare sector has underperformed the market by -80.9% in the past 5 Years.

Dividend Adjusted Return Jul 17, 2020 - Jul 18, 2025



Amgen (AMGN)

Healthcare / Drug Manufacturers - General

StockRover

Stock Report | July 19, 2025

Overall Rating
vs. Peers






57

Ratings scores are relative to industry groups. They compare key metrics to rank stocks vs. their competitors. For example, higher growth than peers will score high even when the absolute growth is below the market average.











Growth vs Peers

Ticker	Company	Growth Rating vs. Peer	Sales QoQ Chg.	Eps QoQ Chg.	Sales Growth Next Y.	Sales 1Y Chg (%)	Sales 3Y Avg (%)	Sales 5Y Avg (%)
GILD	Gilead Sciences	91	-0.3%	-	3.7%	3.3%	1.5%	5.3%
AMGN	Amgen	86	9.4%	-	1.9%	10.3%	8.9%	7.0%
BMJ	Bristol-Myers Squibb	76	-5.6%	-	-6.9%	2.4%	0.3%	6.4%
SNY	Sanofi	71	9.1%	76.9%	7.2%	6.1%	2.4%	3.7%
PFE	Pfizer	62	-7.8%	-5.4%	-0.3%	13.2%	-14.9%	4.9%

Valuation vs Peers

Ticker	Company	Valuation Rating vs. Peer	P/E	Fwd. P/E	PEG Trailing	P/S	P/B	5Y P/E Range
SNY	Sanofi	81	16.6	9.6	-	2.3	1.4	8.3  34.9
PFE	Pfizer	80	17.7	7.9	-	2.2	1.5	6.3  -
GILD	Gilead Sciences	56	22.7	12.7	1.7	4.7	7.0	9.9  -
BMJ	Bristol-Myers Squibb	43	17.7	7.8	-	2.0	5.5	12.2  -
AMGN	Amgen	19	26.9	13.7	-	4.7	25.5	14.9  56.6

Efficiency vs Peers

Ticker	Company	Efficiency Rating vs. Peer	Gross Margin	Operating Margin	Net Margin	5Y ROE Range	5Y ROA Range
BMJ	Bristol-Myers Squ...	87	70.5%	16.5%	11.4%	-54.8%  31.2%	-9.5%  8.4%
GILD	Gilead Sciences	77	78.3%	37.4%	20.8%	0.7%  34.4%	0.2%  11.3%
AMGN	Amgen	76	63.0%	21.8%	17.4%	52.8%  624.8%	3.4%  12.3%
SNY	Sanofi	71	70.9%	22.2%	14.0%	2.9%  9.0%	-0.4%  6.6%
PFE	Pfizer	64	72.3%	24.3%	12.6%	-3.0%  33.6%	-1.2%  16.6%

Financial Strength vs Peers

Ticker	Company	Financial Str. Rating vs. Peers	Debt / Equity	Interest Coverage	Quick Ratio	Intangibles %	Solvency Ratio	Short % of Float
GILD	Gilead Sciences	84	1.3	7.9	1.2	49.0%	25%	1.9%
SNY	Sanofi	67	0.3	15.9	0.7	48.4%	14%	0.2%
PFE	Pfizer	56	0.7	3.5	1.0	58.9%	16%	1.9%
AMGN	Amgen	51	9.2	3.2	0.9	49.7%	15%	2.5%
BMJ	Bristol-Myers Squibb	49	3.0	4.0	1.2	48.2%	19%	1.7%


Dividends vs Peers

Ticker	Company	Dividends Rating vs. Peer	Fwd. Yield	TTM Yield	Price	Fwd. Div. Per Share	Consecutive Div. Growth Years	Payout Ratio
PFE	Pfizer	89	7.0%	7.0%	\$24.47	\$1.72	10+	121.6%
BMJ	Bristol-Myers Squibb	82	5.2%	5.2%	\$47.36	\$2.48	3	90.7%
SNY	Sanofi	71	4.6%	4.6%	\$48.32	\$2.21	2	72.3%
AMGN	Amgen	62	3.2%	3.1%	\$294.76	\$9.52	10+	82.6%
GILD	Gilead Sciences	32	2.9%	2.9%	\$108.22	\$3.16	9	64.9%

Momentum vs Peers

Ticker	Company	Momentum Rating vs. Peer	1M Return	3M Return	6M Return	YTD Return	1Y Return	Beta 1Y	Volatility 1Y	Price vs 52-wk High (%)
GILD	Gilead Sciences	48	0.2%	4.3%	19.5%	18.8%	52.0%	0.36	0.26	90.2%
AMGN	Amgen	31	1.8%	7.2%	10.2%	15.0%	-8.1%	0.48	0.26	85.0%
PFE	Pfizer	26	2.5%	12.6%	-3.6%	-4.5%	-12.1%	0.43	0.23	77.6%
BMJ	Bristol-Myers Squibb	22	2.4%	-2.5%	-13.8%	-13.3%	17.0%	0.27	0.30	74.8%
SNY	Sanofi	21	1.5%	-0.9%	-0.5%	4.6%	0.2%	0.30	0.23	80.4%

DIVIDEND DETAIL



CALENDAR YEAR DIVIDEND HISTORY

Year	Ex-Dividend	Pay Date	Text	Amount
2025 Dividends				\$4.76
	05/16/25	06/06/25	Regular	\$2.38
	02/14/25	03/07/25	Regular	\$2.38
2024 Dividends				\$9.00
	11/18/24	12/09/24	Regular	\$2.25
	08/16/24	09/06/24	Regular	\$2.25
	05/16/24	06/07/24	Regular	\$2.25
	02/15/24	03/07/24	Regular	\$2.25
2023 Dividends				\$8.52
	11/16/23	12/08/23	Regular	\$2.13
	08/17/23	09/08/23	Regular	\$2.13
	05/17/23	06/08/23	Regular	\$2.13
	02/14/23	03/08/23	Regular	\$2.13
2022 Dividends				\$7.76
	11/16/22	12/08/22	Regular	\$1.94
	08/17/22	09/08/22	Regular	\$1.94
	05/16/22	06/08/22	Regular	\$1.94
	02/14/22	03/08/22	Regular	\$1.94
2021 Dividends				\$7.04
	11/15/21	12/08/21	Regular	\$1.76
	08/16/21	09/08/21	Regular	\$1.76
	05/14/21	06/08/21	Regular	\$1.76
	02/11/21	03/08/21	Regular	\$1.76
2020 Dividends				\$6.40

UPCOMING DIVIDEND

Ex-Dividend Date	05/16/25
Payment Date	06/06/25
Amount	\$2.38
Type	Regular

DIVIDEND RATE

Regular Dividend	\$2.38
Forward Dividend Rate	\$9.52
Forward Dividend Yield	3.2%
Trailing 12 Months Dividends	\$9.26
Trailing 12 Months Yield	3.1%

STATISTICS

Payout Ratio	82.6
Dividend Coverage Ratio	1.2
Consecutive Growth Years	10+
3 Year Growth Rate	7.1%
5 Year Growth Rate	8.3%
10 Year Growth Rate	11.7%


FINANCIAL STATEMENT SUMMARY

USD in Millions	Chart	2020	2021	2022	2023	2024	TTM	CAGR
Income Statement								
Revenue		25,424	25,979	26,323	28,190	33,424	34,126	6.7%
Operating Income		9,139	7,639	9,566	7,897	7,258	7,445	-4.4%
Net income		7,264	5,893	6,552	6,717	4,090	5,933	-4.4%
Earnings per share diluted		\$12.31	\$10.28	\$12.11	\$12.49	\$7.56	\$10.97	-2.5%
Average shares diluted		590	573	541	538	541	542	-1.8%
P/E Ratio		18.5	23.2	21.1	20.5	33.3	26.9	8.5%
Balance Sheet								
Cash		10,647	8,037	9,305	10,944	11,973	8,810	-4.1%
Current assets		21,144	19,385	22,186	30,332	29,030	26,929	5.5%
Net Property, Plant and Equipm...		4,889	5,184	5,427	5,941	6,543	6,681	7.1%
Working Capital		9,491	7,201	6,499	11,940	5,931	3,921	-17.7%
Net Debt		22,339	25,272	29,640	53,669	48,126	48,571	18.6%
Stockholders' Equity		9,409	6,700	3,661	6,232	5,877	6,207	-8.7%
Cash Flow								
Operating Cash Flow		10,497	9,261	9,721	8,471	11,490	12,192	3.3%
Cap Ex		-608	-880	-936	-1,112	-1,096	-1,277	17.7%
Free Cash Flow		9,889	8,381	8,785	7,359	10,394	10,915	2.2%
Free Cash Flow per share		\$16.76	\$14.63	\$16.24	\$13.68	\$19.21	\$20.13	4.1%
Profitability								
Operating Margin		35.9%	29.4%	36.3%	28.0%	21.7%	21.8%	-10.4%
Return on Assets		11.8%	9.5%	10.4%	8.3%	4.3%	6.5%	-12.5%
Return on Equity		77.2%	88.0%	179.0%	107.8%	69.6%	95.6%	4.8%
Return on Invested Capital		20.5%	16.9%	18.9%	16.2%	10.1%	14.1%	-7.8%
Dividends								
Dividends Per Share		\$6.40	\$7.04	\$7.76	\$8.52	\$9.00	\$9.52	9.1%
Dividend Yield		3.1%	3.5%	3.2%	3.1%	3.7%	3.2%	1.2%
Dividend Growth		-	10.0%	10.2%	9.8%	5.6%	8.7%	-3.9%
Dividend Coverage		1.9x	1.5x	1.6x	1.5x	0.8x	1.2x	-9.8%

VALUATION & PROFITABILITY HISTORY

Date →		TTM	1 Yr Ago	2 Yrs. Ago	3 Yrs. Ago	4 Yrs. Ago
Price / Earnings		26.9	47.3	15.8	24.1	20.6
Price / Cash Flow		13.1	22.0	14.5	14.8	13.9
Price / Book		25.5	35.4	23.3	143.2	15.1
Price / Tangible B...		-	-	-	-	-
Price / Sales		4.7	6.0	4.8	5.2	5.8
EV / EBITDA		13.5	20.1	10.4	13.3	14.6
Forward Dividend...		3.2%	2.7%	3.7%	3.2%	2.8%
Shareholder Yield		3.2%	2.7%	3.7%	10.0%	6.0%
Gross Margin		63.0%	63.3%	74.2%	75.8%	75.3%
Net Margin		17.4%	10.1%	30.0%	24.9%	22.6%
Return on Assets		6.5%	3.4%	11.4%	10.7%	9.1%
Return on Equity		95.6%	52.8%	117.7%	271.9%	69.7%
ROIC		14.1%	9.3%	14.7%	20.1%	16.9%

WARNINGS

Name	Severity	Details
GAAP Earnings vs. Pro Forma	Medium 	Official EPS: \$3.20; Announced EPS: \$4.90

The GAAP compliant earnings that the company filed with the SEC are less than the pro-forma earnings they announced to the press. Pro-forma earnings can exclude special one-time charges but some distressed companies post these "one-time" charges quarter after quarter.

Downward EPS Revisions	Low 	Net EPS Rev. Cur. Qtr.: -7
------------------------	---	----------------------------

Analyst estimates for the next quarter have been revised down. Check for recent news stories about why the future outlook is darker.

REPORT TIPS

Metric Definitions

Metric descriptions are available at stockrover.com/help/metrics/metric-overview

Quantitative Scores

Our scores analytics is to offer our concise analysis of a stock in powerful, but easy to digest format. Each of the composite score metrics are designed to use the best available accounting practices as well as source data from SEC filings. The scores are computed for a company vs. the market as a whole.

Fair Value

Fair value performs a forecasted discounted cash flow analysis of a company to determine the company's intrinsic value based on the expected future cash flows the company will produce. It basically determines what a company is worth based on how much cash flow it is expected to generate for you in the future,

DISCLAIMER

Financial Statements and Historical Prices Provided by Morningstar. © 2025 Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Stock Rover and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely.

The information provided does not constitute investment advice, nor does it constitute a recommendation to buy or sell any security. Stock Rover LLC and its content providers are not responsible for any losses resulting from trading decisions arising from any use of this information. Past performance is no guarantee of future results.

The information provided is as of the date written and is subject to change without notice

Additional data provided by [Zacks](#), [Intrinio](#), [Quandl](#), [Yodlee](#), [IEX Cloud](#)